Search research articles
Contact Us
Filters
Showing results (911-920 of 1,153) with videos related to
Page
of 116
Sort By:
Annals of Hematology
|
August 8, 2023
The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma-a pooled trials analysis
Luca Fischer, Linmiao Jiang, Joerg Thomas Bittenbring, et al.
Leukemia
|
September 16, 2024
Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trials
Mouhamad Khouja, Linmiao Jiang, Karol Pal, et al.
Haematologica
|
October 26, 2010
Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children
Ilske Oschlies, Birgit Burkhardt, Itziar Salaverria, et al.
Blood
|
May 30, 2015
High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma
Marie-Hélène Delfau-Larue, Wolfram Klapper, Françoise Berger, et al.
Frontiers in Immunology
|
June 30, 2023
Immunodeficiency with susceptibility to lymphoma with complex genotype affecting energy metabolism (<i>FBP1, ACAD9)</i> and vesicle trafficking <i>(RAB27A)</i>
Nina Brauer, Yuto Maruta, Miriam Lisci, et al.
British Journal of Haematology
|
August 11, 2018
Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network
Hilka Rauert-Wunderlich, Anja Mottok, David W Scott, et al.
Leukemia
|
August 20, 2016
Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma
K D Wurster, F Hummel, J Richter, et al.
Blood
|
November 11, 2017
FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy
Anja Mottok, Vindi Jurinovic, Pedro Farinha, et al.
The Lancet. Oncology
|
November 15, 2017
Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group
Dennis A Eichenauer, Annette Plütschow, Stefanie Kreissl, et al.
American Journal of Hematology
|
August 10, 2019
The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma
Sylvia Hartmann, Annette Plütschow, Anja Mottok, et al.
Page
of 116
Search research articles
Search
Showing results (911-920 of 1,153) with videos related to
Sort By:
Page
of 116
Annals of Hematology
|
August 8, 2023
The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma-a pooled trials analysis
Luca Fischer, Linmiao Jiang, Joerg Thomas Bittenbring, et al.
Leukemia
|
September 16, 2024
Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trials
Mouhamad Khouja, Linmiao Jiang, Karol Pal, et al.
Haematologica
|
October 26, 2010
Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children
Ilske Oschlies, Birgit Burkhardt, Itziar Salaverria, et al.
Blood
|
May 30, 2015
High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma
Marie-Hélène Delfau-Larue, Wolfram Klapper, Françoise Berger, et al.
Frontiers in Immunology
|
June 30, 2023
Immunodeficiency with susceptibility to lymphoma with complex genotype affecting energy metabolism (<i>FBP1, ACAD9)</i> and vesicle trafficking <i>(RAB27A)</i>
Nina Brauer, Yuto Maruta, Miriam Lisci, et al.
British Journal of Haematology
|
August 11, 2018
Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network
Hilka Rauert-Wunderlich, Anja Mottok, David W Scott, et al.
Leukemia
|
August 20, 2016
Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma
K D Wurster, F Hummel, J Richter, et al.
Blood
|
November 11, 2017
FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy
Anja Mottok, Vindi Jurinovic, Pedro Farinha, et al.
The Lancet. Oncology
|
November 15, 2017
Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group
Dennis A Eichenauer, Annette Plütschow, Stefanie Kreissl, et al.
American Journal of Hematology
|
August 10, 2019
The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma
Sylvia Hartmann, Annette Plütschow, Anja Mottok, et al.
Page
of 116